or Try an Advanced Search...

    Bemcentinib Stocks List

    Symbol Grade Name % Change
    AVBP C ArriVent BioPharma, Inc. 0.44
    ERAS C Erasca, Inc -1.52
    APTO F Aptose Biosciences, Inc. -10.66
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Biopharmaceutical Cancer Acute Myeloid Leukemia Cancer Therapies NSCLC Solid Tumors Antineoplastic Drugs Bacterial Infections Cancer Treatment Clinical Medicine Colorectal Cancer Drug Resistant Bacterial Infections Drugs Enzymes Gemcitabine Hematologic Malignancies Immunotherapy Lung Cancer Medicine Metastatic Solid Tumors

    Related ETFs - A few ETFs which own one or more of the above listed Bemcentinib stocks.

    Symbol Grade Name Weight
    CNCR F Loncar Cancer Immunotherapy ETF 1.46
    BBC D Virtus LifeSci Biotech Clinical Trials ETF 1.06
    SBIO C ALPS Medical Breakthroughs ETF 0.51
    IWC B iShares Microcap ETF 0.31
    XBI D SPDR S&P Biotech ETF 0.1
    View all Bemcentinib ETFs...
    Compare ETFs
    Compare CNCR to SBIO Compare CNCR to XBI Compare SBIO to IWC

        Bemcentinib Stocks Recent News

        Date Stock Title
        Nov 20 APTO Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
        Nov 15 ERAS Erasca (ERAS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
        Nov 15 AVBP ArriVent BioPharma GAAP EPS of -$0.61 beats by $0.11
        Related Industries: Biotechnology
        Related Stock Lists: Biopharmaceutical Cancer Acute Myeloid Leukemia Cancer Therapies NSCLC Solid Tumors Antineoplastic Drugs Bacterial Infections Cancer Treatment Clinical Medicine Colorectal Cancer Drug Resistant Bacterial Infections Drugs Enzymes Gemcitabine Hematologic Malignancies Immunotherapy Lung Cancer Medicine Metastatic Solid Tumors
        Bemcentinib

        Bemcentinib, also known as BGB324 or R428, is an experimental oral small molecule that is an inhibitor of AXL kinase. Bemcentinib was licensed from Rigel Pharmaceuticals by BerGenBio and currently undergoing six Phase II trials in various solid and hematological tumors as monotherapy and in combination with immunotherapy, chemotherapy, and targeted therapeutics.

        More about Bemcentinib
        Browse All Tags